Factors associated with restoration of the right ventricle function according to 2D-speckle-tracking echocardiography in patients with acute pulmonary embolism

S.M. Sukhova


Background. The purpose was to investigate the possible relation between anamnestic, instrumental and laboratory indicators and restoration of right ventricular (RV) function according to 2D speckle tracking echocardiography (2D STE) in patients with acute pulmonary embolism (PE) in the dynamics of treatment. Materials and methods. The study involved 104 patients with acute PE. All patients were examined using 2D STE, indicators were assessed on the first day of hospital stay and after 3 months of anticoagulant therapy (ACT), which was prescribed during hospitalization by envelope method: rivaroxaban or warfarin. After ACT and according to 2D-STE, residual RV dysfunction has been determined as a segmental ejection fraction of the apical RV segment less than 65 %, and the global longitudinal strain of the free RV wall is less than 18.5 %. Results. After ACT, all the examined patients were divided into two groups: group I included 13 (12.5 %) persons with residual RV dysfunction, group II consisted of 91 (87.5 %) patients with complete restoration of RV function. It was found that type 2 diabetes mellitus (p = 0.04) and chronic cardiac or respiratory failure (p = 0.03) were significantly more likely in the group I; an increase in troponin I (p = 0.05), creatinine (p = 0.009) and fibrinogen (p = 0.05) levels were noted, as well as a decrease in the glomerular filtration rate (p = 0.02) to less than 60 ml/min/1.73 m2. Among patients in group II, significantly more persons received rivaroxaban (p = 0.007), and in the group I — warfarin (p = 0.006). The median of the period from the PE episode to the ACT initiation was 9.0 days in second group and 20.0 days in the first group, p = 0.03. Conclusions. After three months of ACT, residual RV dysfunction remains in 12.5 % of patients with acute PE according to 2D STE. Accor­ding to the regression analysis, in 62.6 % of cases this failure was determined by the presence of such factors, as warfarin therapy, the treatment start date more than 9 days, the presence of type 2 diabetes mellitus and a decrease in the glomerular filtration rate to less than 60 ml/min/1.73 m2.


pulmonary embolism; 2D-speckle-tracking echocardiography; right ventricular dysfunction; effectiveness of treatment


Целуйко В.Й. та ін. Діагностичні можливості 2D-спекл-трекінг ехокардіографії щодо оцінки функції правого шлуночка у хворих на гостру тромбоемболію легеневої артерії / Целуйко В.Й., Яковлева Л.Н., Кіношенко К.Ю., Сухова С.М. // Серце і судини. — 2017. — № 1. — С. 26-32.

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the Euro­pean Socie­ty of Cardiology // European Heart Journal. — 2014, Vol. 35 — № 43. — Р. 3033-3073 doi:10.1093/eurheartj/ehu283.

Altınsoy B. et al. Prognostic Value of Renal Dysfunction Indicators in Normotensive Patients with Acute Pulmonary Embolism / Altınsoy B., Öz İ.İ., Örnek T., Erboy F., Tanrıverdi H., Uygur F., Altintas N., Atalay F., Tor M.M. // Clinical and applied thrombosis hemostasis. — 26 Mar 2016. doi:10.1177/1076029616637440.

Bohacekova M. et al. Risk factors detection in chronic thromboembolic pulmonary hypertension, a tool for risk quantification? / Bohacekova M., Kaldararova M., Valkovicova T., Remkova A., Vesely J., Simkova I. // Bratislava Medical Journal. — 2016. — Vol. 117, № 10. — Р. 577-582. doi:10.4149/bll_2016_112

Donze J. et al. Prospective validation of the Pulmonary Embolism Severity Index. A clinical prognostic model for pulmonary embolism / Donzé J., Le Gal G., Fine M.J., Roy P.M., Sanchez O., Verschuren F., Cornuz J., Meyer G., Perrier A., Righini M., Aujesky D. // Journal of Thrombosis and Haemostasis. — 2008. — Vol. 100, № 5. — P. 943-948. doi:10.1160/TH08-05-0285

Esmon C.T. Targeting factor Xa and thrombin: impact on coagulation and beyond // Journal of Thrombosis and Haemostasis. — 2014. — Vol. 111. — Р. 625-633. doi:10.1160/TH13-09-0730

Feigenbaum H. Echocardiography. — Lippincott Williams & Wilkins, 2012. — 785 р. ISBN/ISSN: 9780781795579

Goldhaber S.Z., Visani L., De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER) // Lancet. — 1999. — Vol. 353, № 9162. — Р. 1386-9.

Goto M. et al. Rivaroxaban, a factor Xa inhibitor, induces the secondary prevention of cardiovascular events after myocardial ischemia reperfusion injury in mice / Goto M., Miura S., Suematsu Y., Idemoto Y., Takata K., Imaizumi S., Uehara Y., Saku K. // International Journal of Cardiology. — 2016. — Vol. 220 — Р. 602-607. doi: 10.10.2016.06.212.

Hofer М. CT Teaching Manual: A Systematic Approach to CT Reading. 4th edition. — MEDIDAK Publishing GmbH, 2013. — Р. 367.

Kasper W. et al. Management Strategies and Determinants of Outcome in Acute Major Pulmonary Embolism: Results of a Multicenter Registry / Kasper W., Konstantinides S., Geibel А., Olschewski М., Heinrich F., Grosser K.D., Rauber K., Iversen S., Redecker M., Kienast J. // J. Am. Coll. Cardiol. — 1997. — Vol. 30, № 5. — Р. 1165-1171. doi:10.1016/S0735-1097(97)00319-7.

Kossaify A. Echocardiographic Assessment of the Right Ventricle, from the Conventional Approach to Speckle Tracking and Three-Dimensional Imaging, and Insights into the «Right Way» to Explore the Forgotten Chamber // Journal Clinical Me­dicine Insights: Cardiology. — 2015. — Vol. 9. — P. 65-75. doi: 10.4137/cmc.s27462.

Lankeit M. et al. Predictive value of the high-sensitivity troponin T assay and the simplified pulmonary embolism severity index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study / Lankeit M., Jimenez D., Kostrubiec M., Dellas C., Hasenfuss G., Pruszczyk P., Konstantinides S. // Circulation. — 2011. — Vol. 124, № 24. — Р. 2716-2724. doi: 10.1161/circulationaha.111.051177.

Le Gal G. et al. Prediction of pulmonary embolism in the emergency department: the revised Geneva score / Le Gal G., Righini M., Roy P.M., Sanchez O., Aujesky D., Bounameaux H., Perrier A. // Annals of Internal Medicine. — 2006. — Vol. 144, № 3. — P. 165-171. doi:10.7326/0003-4819-144-3-200602070-00004.

Marcus J.T. et al. Interventricular mechanical asynchrony in pulmonary arterial hypertension: left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling / Marcus J.T., Gan C.T., Zwanenburg J.J., Boonstra A., Allaart C.P., Gotte M.J., Vonk-Noordegraaf A. // Journal of the American College of Cardiology. — 2008. — Vol. 51, № 7. — Р. 750-757. doi: 10.1016/j.jacc.2007.10.041.

Rosenkranz A.C., Schrör K., Rauch B.H. Direct inhibitors of thrombin and factor Xa attenuate clot-induced mitogenesis and inflammatory gene expression in human vascular smooth muscle cells // Journal of Thrombosis and Haemostasis. — 2011. — Vol. 106, № 3. — Р. 561-562. doi: 10.1160/TH11-04-0275.

Schück O. et al. A new method to estimate glomerular filtration rate based on serum concentration of creatinine, urea and albumin (MDRD, Modification of Diet in Renal Disease) / Schück O., Smrcková J., Teplan V., Stávek P., Skibová J., Stol­lová M. // Vnitr̆ní lékar̆ství. — 2004. — Vol. 50, № 7. — P. 507-509. PMID: 15323257.

Smulders Y.M. Pathophysiology and treatment of haemodynamic instability in acute pulmonary embolism: the pivotal role of pulmonary vasoconstriction // Cardiovascular Research. — 2000. — Vol. 48, № 1. — Р. 23-33. doi: 10.1016/S0008-6363(00)00168-1.

Spronk H., de Jong A.M., Crijns H.J. Pleiotropic effects of factor Xa and thrombin: what to expect from novel anticoagulants // Cardiovascular Research. — 2014. — Vol. 101. — Р. 344-351. doi:10.1093/cvr/cvt343.

Watts J.A. et al. Proinflammatory events in right ventricular damage during pulmonary embolism: effects of treatment with ketorolac in rats / Watts J.A., Gellar M.A., Stuart L.K., Obraztsova M., Kline J.A. // Journal of Cardiovascular Pharmacology. — 2009. — Vol. 54, № 3. — Р. 246-252. doi: 10.1097/fjc.0b013e3181b2b699.

Zhou Q., Bea F., Preusch М. Evaluation of Plaque Stability of Advanced Atherosclerotic Lesions in Apo E-Deficient Mice after Treatment with the Oral Factor Xa Inhibitor Rivaroxaban // Mediators of Inflammation. — 2011. — Vol. 2011. — Art. ID 432080, 9 p. doi: 10.1155/2011/432080.

Zuo P., Zuo Z., Wang X. Factor Xa induces pro-inflammatory cytokine expression in RAW 264.7 macrophages via protease-activated receptor-2 activation // American Journal of Translational Research. — 2015. — Vol. 7, № 11. — Р. 2326-2334. doi: 10.1943-8141/ajtr0014456.

DOI: https://doi.org/10.22141/2224-0586.6.85.2017.111613


  • There are currently no refbacks.

Copyright (c) 2017 EMERGENCY MEDICINE

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2018


   Seo анализ сайта